Strides Pharma shares surged as much as 10% to a day high of Rs 1,056 after USFDA closed its Bengaluru plant inspection with a VAI tag.

The reason was straightforward. Late on Wednesday, the company told stock exchanges that the US drug regulator had wrapped up its review of the company’s main plant with a clean outcome, and the market reacted almost immediately.

Here’s the background. Back in May, the USFDA spent about a week inspecting the Bengaluru facility and flagged five points that needed fixing, issued through what’s called a Form 483.

That’s fairly routine for pharma plants exporting to the US. Strides submitted its corrective response within the deadline, and the regulator has now closed the file with a Voluntary Action Indicated classification.

In simple terms, no further action is needed and the plant continues operating as normal. This isn’t a minor facility either.

It’s the company’s flagship site, producing tablets, capsules and liquid formulations that go out to the US, Europe and other tightly regulated markets, and it makes up a large share of the company’s export revenue.

Additionally, the timing benefits the business. Just weeks earlier, Strides had posted a solid quarter, with revenue up 13% to Rs 1,265.4 crore and profit climbing over 57% year on year.

Growth outside the US was particularly strong, up 17%, while the company also picked up Rs 100 crore in cash by selling a majority stake in its global capability unit, Pivot Path.

Rising freight and operational costs tied to ongoing geopolitical disruptions did squeeze margins slightly during the quarter, but the overall numbers held up well.

By 13:45 pm, Strides Pharma had settled around Rs 996, still up over 4% for the day. Zooming out, shares are now trading close to 9% higher for the year, extending gains as this regulatory overhang clears.

Ready to invest like a pro? Tradz by EquityPandit app equips you with 100+ Free tools and knowledge you need to succeed. Download the Tradz by EquityPandit app and gain access to daily stock lists and insightful market analysis and much more!